New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients

Submitted by amarin on Sun, 11/09/2025 - 21:15
Home
News
New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinf…
DUBLIN and BRIDGEWATER, N.J., Nov. 09, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular care, today highlighted a new  post hoc analysis of aspirin use in REDUCE-IT® reinforcing that icosapent ethyl significantly reduced

Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025

Submitted by amarin on Mon, 11/03/2025 - 13:30
Home
News
Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and …
DUBLIN and BRIDGEWATER, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular care, today announced it will be presenting new findings at the American Heart Association's Scientific Sessions 2025 scheduled for

Amarin Reports Third Quarter 2025 Financial Results

Submitted by amarin on Wed, 10/29/2025 - 11:00
Home
News
Amarin Reports Third Quarter 2025 Financial Results
Company completes transition to fully partnered commercialization model across all international markets Q3 2025 performance reflects initial impact of new approach to Europe, ongoing expansion of Rest-of-World demand, continued success in managing US market, and initial operating margin

Amarin Issues Statement Supporting FDA’s Action to Revise Labeling for Fenofibrate Drugs Reinforcing a Lack of Cardiovascular Benefit

Submitted by amarin on Mon, 10/27/2025 - 12:01
Home
News
Amarin Issues Statement Supporting FDA’s Action to Revise Labeling for Fenofibr…
DUBLIN and BRIDGEWATER, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular care worldwide, today issued the following statement in response to the recent action taken by the U.S.

Amarin to Report Third Quarter 2025 Financial Results and Host Conference Call on October 29, 2025

Submitted by amarin on Wed, 10/15/2025 - 12:01
Home
News
Amarin to Report Third Quarter 2025 Financial Results and Host Conference Call …
DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular care, today announced that it will report third quarter 2025 financial results and conduct a conference call on Wednesday,

Amarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress

Submitted by amarin on Tue, 10/14/2025 - 12:00
Home
News
Amarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT® and EPA Mechan…
DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular care, in collaboration with its Canadian partner HLS Therapeutics, a pharmaceutical company focusing on addressing unmet

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025

Submitted by amarin on Sun, 08/31/2025 - 12:30
Home
News
Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic…

-- Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanisms of Action -- DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 31, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today highlighted in vitro data assessing the effects of EPA on lipoprotein(a) [Lp(a)] oxidation

New REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups

Submitted by amarin on Sat, 08/30/2025 - 12:30
Home
News
New REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZ…
-- 2025 ESC/EAS Dyslipidemia Guideline Focused Update Reaffirms High Dose Icosapent Ethyl as Class IIA Recommended Therapy in High-Risk or Very High-Risk Patients Based on REDUCE-IT -- DUBLIN and BRIDGEWATER, N.J., Aug. 30, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today

New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025

Submitted by amarin on Mon, 08/25/2025 - 12:00
Home
News
New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the Eu…
DUBLIN and BRIDGEWATER, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced upcoming presentations at the European Society of Cardiology (ESC) Congress 2025, August 29 th -September 1 st , in Madrid, Spain, where new data will further illuminate the

Amarin Reports Second Quarter 2025 Financial Results

Submitted by amarin on Wed, 07/30/2025 - 11:00
Home
News
Amarin Reports Second Quarter 2025 Financial Results
-- European Partnership with Recordati Established to Maximize VAZKEPA ® in Europe; Global Corporate Restructuring Implemented with Anticipated $70 Million in Operating Expense Savings Over Next 12 Months --  -- Q2 2025 Financial Performance Reflects Incremental Progress for VASCEPA ® /VAZKEPA ® in
Subscribe to Global